Public Employees Retirement System of Ohio Invests $1.86 Million in Avantor, Inc. $AVTR

Public Employees Retirement System of Ohio acquired a new position in Avantor, Inc. (NYSE:AVTR) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 187,865 shares of the company’s stock, valued at approximately $1,860,000.

Several other large investors have also modified their holdings of AVTR. Private Management Group Inc. increased its stake in Avantor by 50.4% in the fourth quarter. Private Management Group Inc. now owns 2,456,859 shares of the company’s stock worth $28,156,000 after purchasing an additional 823,572 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Avantor during the second quarter valued at $800,000. Oppenheimer Asset Management Inc. bought a new position in shares of Avantor in the second quarter worth about $805,000. Assenagon Asset Management S.A. grew its stake in Avantor by 425.0% in the 2nd quarter. Assenagon Asset Management S.A. now owns 556,871 shares of the company’s stock worth $5,513,000 after acquiring an additional 450,801 shares in the last quarter. Finally, Brickwood Asset Management LLP grew its stake in Avantor by 6,891.9% in the 4th quarter. Brickwood Asset Management LLP now owns 3,184,043 shares of the company’s stock worth $36,489,000 after acquiring an additional 3,138,504 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

AVTR has been the subject of several research analyst reports. Wall Street Zen raised shares of Avantor from a “hold” rating to a “buy” rating in a research note on Saturday, June 27th. TD Cowen reissued a “hold” rating on shares of Avantor in a research note on Wednesday, July 15th. Evercore set a $10.50 price objective on Avantor in a report on Monday, July 6th. Wells Fargo & Company lifted their target price on Avantor from $14.00 to $16.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. Finally, Sanford C. Bernstein started coverage on Avantor in a report on Friday, June 26th. They issued a “market perform” rating and a $10.50 target price for the company. Two equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $12.00.

Avantor Trading Down 0.1%

NYSE:AVTR opened at $14.96 on Monday. Avantor, Inc. has a one year low of $7.26 and a one year high of $15.93. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.18 and a current ratio of 1.78. The firm has a market cap of $10.12 billion, a P/E ratio of -17.81, a P/E/G ratio of 11.30 and a beta of 0.89. The firm has a 50-day simple moving average of $12.62 and a 200-day simple moving average of $9.94.

Avantor (NYSE:AVTR) last released its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. The firm had revenue of $1.69 billion for the quarter, compared to the consensus estimate of $1.61 billion. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The company’s quarterly revenue was up .5% on a year-over-year basis. During the same period last year, the firm earned $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. Equities analysts anticipate that Avantor, Inc. will post 0.81 EPS for the current fiscal year.

Avantor Company Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.